Analysis of the English name and international pharmacopoeia standards of fenelidone (Keshenda)

Finerenone (Finerenone) is a new type of non-steroidal mineral corticoid receptor antagonist (MRA), its English name is Finerenone. This drug is mainly used for patients with chronic kidney disease (CKD) combined with type 2 diabetes to reduce the progression of kidney disease and the risk of cardiovascular events. FinerenoneDue to its non-steroidal structure, it is more selective than traditional spironolactone and eplerenone, has high affinity for mineralocorticoid receptors, and has a lower incidence of side effects such as hyperkalemia.

In the international pharmacopoeia and pharmaceutical standards, Finerenone is listed as a prescription drug, and the drug ingredients, purity and content are strictly regulated. For example, in the European Pharmacopoeia (European Pharmacopoeia) and the United States Pharmacopoeia (USP, United States Pharmacopeia), the quality control indicators of Finerenone include appearance, melting point, solubility, content uniformity and impurity limits to ensure the stability and safety of the drug in production and circulation. These standards provide assurance of drug consistency and clinical efficacy.

FinerenoneThe storage conditions and stability requirements are also clarified in the Pharmacopoeia. Drugs usually need to be protected from light, sealed and kept stable within a specified temperature range. Pharmacopoeia standards also set forth requirements for its preparation form (such as tablets) and dissolution rate to ensure that the active ingredients can be quickly released and absorbed after oral administration to achieve the expected clinical efficacy.

In general, Finerenone is an internationally regulated non-steroidal MRA, and its English name and pharmacopoeia standards provide important reference for clinical use. Through strict quality control and consistency standards, the comparability and safety of drugs across different regions and pharmaceutical companies are ensured, providing reliable treatment options for patients with chronic kidney disease.

Reference link:https://www.drugs.com